Literature DB >> 30528043

PD-1/PD-L1 expressions in medullary thyroid carcinoma: Clinicopathologic and prognostic analysis of Chinese population.

Yalan Bi1, Xinyu Ren1, Xiaohui Bai1, Yunxiao Meng1, Yufeng Luo1, Jinling Cao1, Yuhan Zhang1, Zhiyong Liang2.   

Abstract

INTRODUCTION: Few studies have focused on PD-L1 expression in medullary thyroid carcinoma (MTC). Expressions of PD-1 and PD-L1 and their clinicopathologic and prognostic relevance were therefore further investigated on a relatively large population of MTC patients.
MATERIALS AND METHODS: Surgical specimens were obtained from 87 MTC patients during a median follow-up of 37.7 months. PD-1 and PD-L1 expressions on tumor and associated immune cells were studied immunohistochemically using >1% positive cells as a threshold for positivity. Their correlations with clinicopathologic and prognostic feature were analyzed.
RESULTS: PD-1 and PD-L1 were positively stained in 22 and 19 MTC patients. Most PD-L1-positive cases (18/19) showed weak to moderate staining intensity. PD-1 and PD-L1 were co-expressed in 11 patients. PD-L1 positivity was significantly correlated with distant metastases at surgery (21.1% vs 1.5%, P = 0.007). Coexpression of PD-1 and PD-L1 in MTC was correlated with advanced pathologic TNM stage III/IV (P = 0.040) and distant metastases at surgery (P = 0.013). However, there was no other clinicopathologic and prognostic relevance regarding to PD-1, PD-L1 or their coexpression in our MTC patients.
CONCLUSION: PD-1/PD-L1 pathway was expressed in MTC patients and was significantly correlated with the distant metastases at surgery, which may shed light on PD-1/PD-L1 as a promising therapeutic target in MTC. Future better understanding of PD-1/PD-L1 expression and their relationship with immunotherapy response may provide direct evidence for management of refractory MTC.
Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Distant metastasis at surgery; Medullary thyroid carcinoma (MTC); Overall survival; Programmed cell death protein 1 (PD-1); Programmed death-ligand 1 (PD-L1); Progression free survival

Mesh:

Substances:

Year:  2018        PMID: 30528043     DOI: 10.1016/j.ejso.2018.10.060

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  11 in total

1.  Clinical significance and interrelations of PD-L1 expression, Ki-67 index, and molecular alterations in sporadic medullary thyroid carcinoma from a Chinese population.

Authors:  Yanhua Bai; Ting Guo; Dongfeng Niu; Yanli Zhu; Wenhao Ren; Qian Yao; Xiaozheng Huang; Qin Feng; Tianxiao Wang; Xiuli Ma; Xinqiang Ji
Journal:  Virchows Arch       Date:  2022-08-03       Impact factor: 4.535

Review 2.  Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.

Authors:  Antonio Matrone; Carla Gambale; Alessandro Prete; Rossella Elisei
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-29       Impact factor: 6.055

Review 3.  Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy.

Authors:  María San Román Gil; Javier Pozas; Javier Molina-Cerrillo; Joaquín Gómez; Héctor Pian; Miguel Pozas; Alfredo Carrato; Enrique Grande; Teresa Alonso-Gordoa
Journal:  Int J Mol Sci       Date:  2020-07-13       Impact factor: 5.923

Review 4.  From biomarkers to therapeutic targets: the promise of PD-L1 in thyroid autoimmunity and cancer.

Authors:  Grégoire D'Andréa; Sandra Lassalle; Nicolas Guevara; Baharia Mograbi; Paul Hofman
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

5.  Association between programmed cell death ligand 1 expression and thyroid cancer: A meta-analysis.

Authors:  Baoyu Wan; Pengyi Deng; Wenli Dai; Peng Wang; Zhizhi Dong; Chaojun Yang; Jinling Tian; Tao Hu; Kai Yan
Journal:  Medicine (Baltimore)       Date:  2021-04-09       Impact factor: 1.817

Review 6.  Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?

Authors:  Sergio Di Molfetta; Andrea Dotto; Giuseppe Fanciulli; Tullio Florio; Tiziana Feola; Annamaria Colao; Antongiulio Faggiano
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-14       Impact factor: 5.555

Review 7.  Molecular Imaging and Theragnostics of Thyroid Cancers.

Authors:  Luca Giovanella; Desiree' Deandreis; Alexis Vrachimis; Alfredo Campenni; Petra Petranovic Ovcaricek
Journal:  Cancers (Basel)       Date:  2022-03-01       Impact factor: 6.639

Review 8.  Metastatic medullary thyroid carcinoma: a new way forward.

Authors:  Anna Angelousi; Aimee R Hayes; Eleftherios Chatzellis; Gregory A Kaltsas; Ashley B Grossman
Journal:  Endocr Relat Cancer       Date:  2022-05-31       Impact factor: 5.900

9.  Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.

Authors:  Aparna Hegde; Alexander Y Andreev-Drakhlin; Jason Roszik; Le Huang; Shuang Liu; Kenneth Hess; Maria Cabanillas; Mimi I Hu; Naifa L Busaidy; Steven I Sherman; Ramona Dadu; Elizabeth G Grubbs; Siraj M Ali; Jessica Lee; Yasir Y Elamin; George R Simon; George R Blumenschein; Vassiliki A Papadimitrakopoulou; David Hong; Funda Meric-Bernstam; John Heymach; Vivek Subbiah
Journal:  ESMO Open       Date:  2020-10

10.  Expression of PD-L1 in medullary thyroid carcinoma-a new therapeutic target?

Authors:  Liliana Fonseca; Cláudia Freitas; Ana Caramelo; Catarina Eloy
Journal:  Endocrinol Diabetes Metab       Date:  2021-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.